¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  : 2019-06-01
±³À°ÀÏÀÚ : 2019-06-01
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  
ÁÖÃÖ±â°ü : °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø
´ã´çÀÚ : ±èµµÈ­
¿¬¶ôó : 02-2258-3005  
À̸ÞÀÏ : hh@cmcnu.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ-40,000¿ø / Àü°øÀÇ °£È£»ç-20,000¿ø ´çÀϵî·Ï : Àü¹®ÀÇ-50,000¿ø / Àü°øÀÇ °£È£»ç-30,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:30~10:20 Registration  () 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:20~10:30 Opening remarks  ±èµ¿¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:30~11:00 Minimal residual disease in acute myeloid leukemia and myelodysplastic syndrome  Á¶º´½Ä(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:00~11:30 Biology and Current management for Primary myelofibrosis  ¾ö±â¼º(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:30~12:00 Recent updates in management of Plasma cell myeloma  ¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ) 
½Ä»ç 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:00~13:00 ½Ä»ç  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:00~13:40 Strategies to overcome chemotherapy resistance by controlling tumor microenvironment  ÀÌÈ£¿µ(¼­¿ï´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:40~14:20 Translational hematology research for aging and cell therapy using non-human primate hematopoietic stem cells  À¯°æ·Ï(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:20~15:00 Cell fate determinants in leukemic progression  ±ÇÇõ¿µ(¼øõÇâ´ëÇб³) 
È޽Ġ06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:00~15:15 Coffee break  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:15~15:45 Basic Immunology: Harnessing T cells for adoptive cell therapy  ¹ÚÀ±(Çѱ¹°úÇбâ¼ú¿ø) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:45~16:15 Future treatment options using CAR-T cell: From Clinician¡¯s Perspective  ÀÌÀç¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:15~16:45 Practical consideration on manufacturing and commercialization of CAR-T and beyond: From an Industrial Perspective  ±è¼¼¿ø(SL-BIGEN) 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:45~17:00 Closing remarks  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2019 (Á÷¼±Á¦)´ëÇÑ»êºÎÀΰúÀÇ»çȸ Àü±¹¼øȸ¼¼¹Ì³ª : 2019-06-01
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø 2019³âµµ ´ëÀü±¤¿ª½ÃÁß±¸,¼­±¸ÀÇ»çȸ Çмú´ëȸ : 2019-06-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
990 ºÎ»ê ´ëÇÑ»êºÎÀΰúÇÐȸ ºÎ»êÁöȸ 10¿ù Çмú¸ðÀÓ : 2018-10-02 0 653 2018-09-28
989 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ´ëÇÑÀ忬±¸ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¤±âÁý´ãȸ : 2018-10-01 0 399 2018-09-28
988 ¼­¿ï 2018 Áß¾Ó´ëÇб³º´¿ø ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-30 0 383 2018-09-28
987 ¼­¿ï »ï¼º¼­¿ïº´¿ø ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ 2018 CAOS-KOREA Ãß°èÇмú´ëȸ : 2018-09-29 0 2,021 2018-09-28
986 ÀÎõ °¡Å縯´ëÇб³ÀÎõ¼º¸ðº´¿ø ¿Ü°ú Àü°øÀÇ ÀüÀÓÀǸ¦ À§ÇÑ ¿¬±¸¼ú±â¿öÅ©¼¥ : 2018-09-29 0 1,059 2018-09-28
985 ±¤ÁÖ Àü³²´ëÇб³º´¿ø Á¦14ȸ ±¤ÁÖ ½ÉÀüµµ ½ÉÆ÷Áö¿ò (GUESS) : 2018-09-29 0 1,724 2018-09-28
984 °æ±â ¼øõÇâ´ëÇб³ºÎõº´¿ø °æ±¸°­ °©»ó¼± ÀýÁ¦¼ú : 2018-09-28 0 1,952 2018-09-28
983 Àü³² 2018³âµµ ´ëÇÑÅëÁõÇÐȸ ôÃß³»½Ã°æ Ä«µ¥¹Ù¿öÅ©¼ó_ôÃß³»½Ã°æ Ä«µ¥¹Ù ¿öÅ©¼ó : 2018-10-28 0 811 2018-09-19
982 °æ±â 2018³â Á¦ 2ȸ °³¿øÀǸ¦ À§ÇÑ ºÎõ¼º¸ðº´¿ø À¯¹æ-°©»ó¼± ¿¬¼ö°­Á -¿Ü·¡¿¡¼­ ²À ÇÊ¿äÇÑ À¯¹æ-°©»ó¼± ÁúȯÀÇ ÃÖ½ÅÁö°ß- : 2018-10-28 0 2,310 2018-09-19
981 ¼­¿ï 2018³âµµ ¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­Á : 2018-10-28 0 775 2018-09-19
980 ¼­¿ï 2018 ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ ÀÇÇÐÀ¯ÀüÇÐ ¿¬¼ö°­Á : 2018-10-28 0 828 2018-09-19
979 Àü³² 2018³âµµ ´ëÇÑÅëÁõÇÐȸ ôÃß³»½Ã°æ Ä«µ¥¹Ù¿öÅ©¼ó_ÃÊÀ½ÆÄ Ä«µ¥¹Ù ¿öÅ©¼ó : 2018-10-27 0 807 2018-09-19
978 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇÐȸ 2018³â Ãß°èÇмú´ëȸ : 2018-10-27 0 911 2018-09-19
977 ¼­¿ï Á¦3±â¡¸Áö¿ª»çȸ °øÁߺ¸°Ç ÃÖ°í¸®´õ °úÁ¤¡¹10:°øÁߺ¸°Ç ÀÀ±Þ/À§±â »óȲ¿¡¼­ °øÁߺ¸°ÇÀü¹®°¡ÀÇ ¿ªÇÒ : 2018-10-26 0 866 2018-09-19
976 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇÐȸ 2018³â Ãß°èÇмú´ëȸ : 2018-10-26 0 706 2018-09-19
1341 | 1342 | 1343 | 1344 | 1345 | 1346 | 1347 | 1348 | 1349 | 1350
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷